FRES Fresh2 Group: Total Company Value-to-Revenue Ratio

Corporate company logo of Fresh2 (FRES)

The Enterprise Value to Sales ratio demonstrates how trade wars between the US and China are undermining logistics and reducing the profitability of Fresh2 Group Limited (FRES). The current level stands at , highlighting a lack of pricing power and the vulnerability of the micro-cap structure to dumping. However, Fresh2 Group Limited (FRES) is pursuing expansion by implementing IT platforms for early disease screening to capture market share in laboratory diagnostics.

Fresh2 Group - FRES Enterprise Value-to-Revenue Ratio (period 07/04/2022 - 11/20/2026)

Analytical breakdowns for fresh2.co (FRES)

- price and consensus price forecast:
- company stock capitalization data:
Fundamental company analysis:Fresh2 Group - FRES
Mass-produced product of Fresh2 Group Limited

The scaling of Fresh2 Group Limited operations through the aggressive hiring of IT specialists and laboratory technicians directly impacts the EV/Sales multiple, which compares the total enterprise value to revenue while excluding the impact of debt. Analyzing this metric helps identify the risk of asset overvaluation, where market optimism outpaces the actual efficiency of the medical core, creating the threat of a sudden price correction should market conditions shift.

Key competitors

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|luciddx.com (LUCD) - Enterprise Value-to-Revenue Multiple|prenetics.com - EV/Sales Multiple|Insight Molecular Diagnostics, Inc. (IMDX) - Company Value to Revenue|TRIB: EV/Sales Multiple|ProPhase - Business Value to Revenue|Enterprise Value-to-Revenue Ratio ainos.com|CODX: Business Value to Revenue|Enterprise Value-to-Revenue Ratio HeartSciences (HSCS)|Company Value to Revenue Biomerica Inc. BMRA|EV/Sales Multiple CDIO (Cardio Diagnostics)|ONCO - Company Value to Revenue|VRAX: Company Value to Revenue|bluejaydx.com (BJDX) - Company Value to Revenue|AWH: EV/Sales Multiple|AXDX: Enterprise Value-to-Revenue Coefficient|CNTG (CENTOGENE N.V.) - EV/Sales Multiple|Company Value to Revenue Enzo Biochem, Inc. (ENZ)|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue